Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + placebo
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Erlotinib + placebo refers to a combination used in clinical trials where one group receives erlotinib and the other receives a matching placebo for comparison. Erlotinib is an oral small molecule tyrosine kinase inhibitor that selectively targets the epidermal growth factor receptor (EGFR) tyrosine kinase, blocking its activity and thereby inhibiting cancer cell proliferation and survival. It is primarily indicated for non-small cell lung cancer (NSCLC) with specific EGFR mutations, as well as advanced pancreatic cancer in combination with gemcitabine. Placebo is an inert substance used as a control in clinical studies to assess the efficacy of active drugs like erlotinib[1][2][3][7].
- Brand names
- Tarceva
- Other names
- erlotinib alone
02
Targets
Beyond the preview
Go deeper on erlotinib + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + placebo.